interferon in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
1.74 [0.51 ; 5.93 ] Kalil (ACTT-3), 2021 1 0% 969 NA not evaluable deathsdetailed results Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
SPRINTER, 2022 0.79 [0.38; 1.66]
Synairgen SG016, 2020 0.16 [0.01; 3.31]
0.92 [0.42 ; 1.98 ] Kalil (ACTT-3), 2021, SPRINTER, 2022, Synairgen SG016, 2020 3 19% 1,693 low not evaluable deaths (time to event analysis only)detailed results Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
1.74 [0.51 ; 5.93 ] Kalil (ACTT-3), 2021 1 0% 969 NA not evaluable clinical deteriorationdetailed results SPRINTER, 2022 0.69 [0.43; 1.11]
Synairgen SG016, 2020 0.50 [0.18; 1.38]
0.65 [0.42 ; 1.00 ] SPRINTER, 2022, Synairgen SG016, 2020 2 0% 724 NA not evaluable clinical improvementdetailed results Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
Synairgen SG016, 2020 2.32 [1.07; 5.04]
1.39 [0.61 ; 3.14 ] Kalil (ACTT-3), 2021, Synairgen SG016, 2020 2 78% 969 moderate not evaluable clinical improvement (14-day)detailed results Kalil (ACTT-3), 2021 1.01 [0.79; 1.29]
1.01 [0.79 ; 1.29 ] Kalil (ACTT-3), 2021 1 0% 969 NA not evaluable clinical improvement (28-day)detailed results Synairgen SG016, 2020 3.15 [1.39; 7.14]
3.15 [1.39 ; 7.14 ] Synairgen SG016, 2020 1 0% 101 NA not evaluable clinical improvement (time to event analysis only)detailed results Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
SPRINTER, 2022 1.02 [0.81; 1.28]
1.00 [0.89 ; 1.12 ] Kalil (ACTT-3), 2021, SPRINTER, 2022 2 0% 1,592 moderate not evaluable death or ventilationdetailed results SPRINTER, 2022 0.85 [0.45; 1.61]
Synairgen SG016, 2020 0.38 [0.09; 1.63]
0.75 [0.42 ; 1.34 ] SPRINTER, 2022, Synairgen SG016, 2020 2 0% 623 NA not evaluable hospital dischargedetailed results SPRINTER, 2022 1.06 [0.89; 1.27]
Synairgen SG016, 2020 1.63 [0.61; 4.35]
1.07 [0.90 ; 1.28 ] SPRINTER, 2022, Synairgen SG016, 2020 2 0% 724 NA not evaluable hospitalizationdetailed results Jagannathan, 2020 1.00 [0.14; 7.34]
1.00 [0.14 ; 7.34 ] Jagannathan, 2020 1 0% 120 NA not evaluable Recovery (time to event analysis only)detailed results SPRINTER, 2022 1.02 [0.81; 1.28]
1.02 [0.81 ; 1.28 ] SPRINTER, 2022 1 0% 623 NA not evaluable viral clearance detailed results Jagannathan, 2020 0.81 [0.56; 1.18]
0.81 [0.56 ; 1.18 ] Jagannathan, 2020 1 0% 120 NA not evaluable viral clearance (time to event analysis only)detailed results Jagannathan, 2020 0.81 [0.56; 1.18]
0.81 [0.56 ; 1.18 ] Jagannathan, 2020 1 0% 120 NA not evaluable recoverydetailed results Synairgen SG016, 2020 2.19 [1.03; 4.67]
2.19 [1.03 ; 4.67 ] Synairgen SG016, 2020 1 0% 101 NA not evaluable serious adverse eventsdetailed results Jagannathan, 2020 1.00 [0.14; 7.34]
1.00 [0.14 ; 7.34 ] Jagannathan, 2020 1 0% 120 NA not evaluable adverse eventsdetailed results Jagannathan, 2020 1.33 [0.63; 2.78]
1.33 [0.63 ; 2.78 ] Jagannathan, 2020 1 0% 120 NA not evaluable 0.5 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-22 14:45 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 517,881,904,882,897,896,899,1235,898,687,740,883,947
- roots T: 290
